Ebola Vaccine Based on the 2014 Zaire Guinea Epidemic Strain

Recombinant adenovirus type-5–vectored Ebola vaccine in high doses was safe and immunogenic in healthy Chinese adults.

The ongoing Ebola epidemic has spurred efforts to develop a vaccine (NEJM JW Infect Dis Jan 2015 and N Engl J Med 2014 Nov 26; [e-pub]). Now, investigators in China have published the results of a phase I, double-blind trial testing the safety and immunogenicity of a novel recombinant adenovirus type-5 vector–based vaccine based on the 2014 Zaire Guinea epidemic strain.

In this partially industry-supported trial, 120 healthy, HIV-negative adults were randomized to receive placebo or high- or low-dose vaccine by intramuscular injection. At baseline, approximately 60% of the participants had pre-existing adenovirus type-5 neutralizing antibody titers >1:200.

At day 28, all high-dose and 38 of 40 low-dose recipients had Ebola glycoprotein–specif…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Ebola Vaccine Based on the 2014 Zaire Guinea Epidemic Strain

Topics

Reviewing Author